Logo for MannKind Corporation

MannKind Investor Relations Material

Latest events

Logo for MannKind Corporation

Q4 2023

MannKind
Logo for MannKind

Q4 2023

27 Feb, 2024
Logo for MannKind

Q3 2023

7 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from MannKind Corporation

Access all reports
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza (insulin human), a small molecule inhalation powder that delivers rapid insulin absorption directly into the bloodstream. Its product portfolio also includes Technosphere dry powder inhalation system and pulmonary delivery devices.